Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives

Frédéric Bigot; Clément Bonnet; Christophe Massard

doi:10.1016/j.bulcan.2017.01.009

Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives

Titre traduit de la contribution: Les avancées de l'immunothérapie dans la prise en charge des patients atteints de tumeurs génito-urinaires

Frédéric Bigot, Clément Bonnet, Christophe Massard

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

1 Citation (Scopus)

Résumé

Management of genitourinary (GU) cancers is improving rapidly with the development of immunotherapy agents, especially anti-PD-1/anti-PD-L1 therapies. Large studies have shown better outcomes for the treatment of these patients, leading to new drug approvals and recent changes in standards of care in renal, prostate and bladder cancer. We performed a review of recent studies assessing efficacy of immuno-oncology therapies in GU cancers. New results are summarized and next ways of development of clinical research are discussed as the use of such therapies will soon be assessed in first-line or adjuvant settings.

Titre traduit de la contribution	Les avancées de l'immunothérapie dans la prise en charge des patients atteints de tumeurs génito-urinaires
langue originale	Anglais
Pages (de - à)	370-379
Nombre de pages	10
journal	Bulletin du Cancer
Volume	104
Numéro de publication	4
Les DOIs	https://doi.org/10.1016/j.bulcan.2017.01.009
état	Publié - 1 avr. 2017

Accès au document

10.1016/j.bulcan.2017.01.009

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{0428f03935c74529a9a0d0d2979abf92,

title = "Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives",

abstract = "Management of genitourinary (GU) cancers is improving rapidly with the development of immunotherapy agents, especially anti-PD-1/anti-PD-L1 therapies. Large studies have shown better outcomes for the treatment of these patients, leading to new drug approvals and recent changes in standards of care in renal, prostate and bladder cancer. We performed a review of recent studies assessing efficacy of immuno-oncology therapies in GU cancers. New results are summarized and next ways of development of clinical research are discussed as the use of such therapies will soon be assessed in first-line or adjuvant settings.",

keywords = "Genitourinary cancer, Immunotherapy, Review",

author = "Fr{\'e}d{\'e}ric Bigot and Cl{\'e}ment Bonnet and Christophe Massard",

note = "Publisher Copyright: {\textcopyright} 2017 Soci{\'e}t{\'e} Fran{\c c}aise du Cancer",

year = "2017",

month = apr,

day = "1",

doi = "10.1016/j.bulcan.2017.01.009",

language = "English",

volume = "104",

pages = "370--379",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "4",

}

TY - JOUR

T1 - Immunotherapy for the treatment of patients with genitourinary cancers

T2 - Review and perspectives

AU - Bigot, Frédéric

AU - Bonnet, Clément

AU - Massard, Christophe

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Management of genitourinary (GU) cancers is improving rapidly with the development of immunotherapy agents, especially anti-PD-1/anti-PD-L1 therapies. Large studies have shown better outcomes for the treatment of these patients, leading to new drug approvals and recent changes in standards of care in renal, prostate and bladder cancer. We performed a review of recent studies assessing efficacy of immuno-oncology therapies in GU cancers. New results are summarized and next ways of development of clinical research are discussed as the use of such therapies will soon be assessed in first-line or adjuvant settings.

AB - Management of genitourinary (GU) cancers is improving rapidly with the development of immunotherapy agents, especially anti-PD-1/anti-PD-L1 therapies. Large studies have shown better outcomes for the treatment of these patients, leading to new drug approvals and recent changes in standards of care in renal, prostate and bladder cancer. We performed a review of recent studies assessing efficacy of immuno-oncology therapies in GU cancers. New results are summarized and next ways of development of clinical research are discussed as the use of such therapies will soon be assessed in first-line or adjuvant settings.

KW - Genitourinary cancer

KW - Immunotherapy

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85013356920&partnerID=8YFLogxK

U2 - 10.1016/j.bulcan.2017.01.009

DO - 10.1016/j.bulcan.2017.01.009

M3 - Review article

C2 - 28237355

AN - SCOPUS:85013356920

SN - 0007-4551

VL - 104

SP - 370

EP - 379

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 4

ER -